| Catalog No. | HY422046 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Isotype | Fusion - [ICOSLG N-terminal fragment (1-122)]2 - IGHG1 Fc (Fragment constant) |
|---|
| Expression system | Mammalian Cells |
|---|
| Target | CD28, TP44, T-cell-specific surface glycoprotein CD28, CD278, ICOS, Inducible T-cell costimulator, Activation-inducible lymphocyte immunomediatory molecule, AILIM |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | P10747 & Q9Y6W8 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | ALPN-101,ICOSLvIgD-Fc,CAS:2270247-50-0 |
|---|
| Background | Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
